Thompson Siegel & Walmsley’s ResMed RMD Stock Holding History

Thompson Siegel & Walmsley’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-688	Closed	-$68K	–	821
2018 Q1	$68K	Hold	688	–	–	﹤0.01%	497
2017 Q4	$58K	Hold	688	–	–	﹤0.01%	518
2017 Q3	$53K	Hold	688	–	–	﹤0.01%	514
2017 Q2	$54K	Buy	+688	New	+$49.2K	﹤0.01%	524
2015 Q4	–	Sell	-233	Closed	-$12K	–	722
2015 Q3	$12K	Hold	233	–	–	﹤0.01%	597
2015 Q2	$13K	Hold	233	–	–	﹤0.01%	594
2015 Q1	$17K	Sell	233 -9,458	-98%	-$614K	﹤0.01%	580
2014 Q4	$543K	Sell	9,691 -802,117	-99%	-$41.9M	0.01%	323
2014 Q3	$40M	Buy	811,808 +57,958	+8%	+$2.95M	0.8%	28
2014 Q2	$38.2M	Buy	753,850 +144,108	+24%	+$7.14M	0.74%	26
2014 Q1	$27.2M	Buy	609,742 +311,500	+104%	+$14M	0.61%	37
2013 Q4	$14M	Buy	+298,242	New	+$15.1M	0.33%	132

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Thompson Siegel & Walmsley's RMD Position: Q2 2018 in Review

Thompson Siegel & Walmsley sold out of ResMed (RMD) in Q2 2018, closing a stake of 688 shares — an estimated $68K sold.

Thompson Siegel & Walmsley first reported a position in RMD in Q4 2013 and held it in 12 quarters. The position peaked at $40M in Q3 2014. 465 funds tracked by Wall St. Rank hold RMD as of Q2 2018.

Thompson Siegel & Walmsley reported no remaining ResMed position as of Q2 2018 after selling out during the quarter.
Thompson Siegel & Walmsley sold 688 ResMed shares in Q2 2018, an estimated $68K.
Thompson Siegel & Walmsley first reported a position in ResMed in Q4 2013 and held it in 12 quarters.
Thompson Siegel & Walmsley's ResMed position peaked at $40M in Q3 2014.
465 funds tracked by Wall St. Rank held ResMed as of Q2 2018.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2018, filed 9 Aug 2018.